P2Y12 inhibitor monotherapy following dual antiplatelet therapy (DAPT) discontinuation after percutaneous coronary intervention (PCI) is associated with a significantly lower risk for myocardial infarction (MI) than aspirin monotherapy and with similar risks of major bleeding between the two regimens, according to a new meta-analysis.